

1644
**Sterne Kessler
 Goldstein Fox**

ATTORNEYS AT LAW



Robert Greene Sterne
 Edward J. Kessler
 Jorge A. Goldstein
 David K.S. Cornwell
 Robert W. Esmond
 Tracy-Gene G. Durkin
 Michael A. Cimbala
 Michael B. Ray
 Robert E. Sokohl
 Eric K. Steffe
 Michael Q. Lee
 Steven R. Ludwig
 John M. Covert
 Linda E. Alcorn
 Robert C. Milligan
 Lawrence B. Bugaiksy
 Donald J. Featherstone
 Michael V. Messinger

Judith U. Kim
 Timothy J. Shea, Jr.
 Patrick E. Garrett
 Jeffrey T. Hevey*
 Heidi L. Kraus
 Edward W. Yee
 Albert L. Ferro*
 Donald R. Banowitz
 Peter A. Jackman
 Molly A. McCall
 Teresa U. Medler
 Jeffrey S. Weaver
 Kendrick P. Patterson
 Vincent L. Capuano
 Albert J. Fasulo II*
 Eldora Ellison Floyd
 Thomas C. Fiala
 Brian J. Del Buono

Virgil Lee Beaston*
 Kimberly N. Reddick
 Theodore A. Wood
 Elizabeth J. Haanes
 Bruce E. Chalker
 Joseph S. Ostroff
 Frank R. Cunningham
 Christine M. Lhuillier
 Rae Lynn Prengaman
 Jane Shershenovich*
 Lawrence J. Carroll*
 George S. Bardmesser
 Daniel A. Klein*
 Rodney G. Maze
 Jason D. Eisenberg
 Michael A. Specht*
 Andrea J. Kamage
 Tracy L. Muller*

Jon E. Wright*
 LuAnne M. Yuricek*
Registered Patent Agents
 Karen R. Markowicz
 Nancy J. Leith
 Ann E. Summerfield
 Helena C. Carlson
 Gaby L. Longsworth
 Matthew J. Dowd
 Aaron L. Schwartz
 Angelique G. Uy
 Boris A. Matverko
 Mary B. Tung
 Katrina Y. Pei
 Bryan L. Skelton
 Robert A. Schwartzman
 John J. Figueroa

1644
 Timothy A. Doyle
 Jennifer R. Mahalingappa
 Teresa A. Colella
 Victoria S. Lundgren
 W. Brian Edge
Senior Counsel
 Samuel L. Fox
 Kenneth C. Bass III
 Lisa A. Dunner
 *Admitted only in Maryland
 *Admitted only in Virginia
 *Admitted only in Texas
 •Practice Limited to
 Federal Agencies

March 19, 2003

R#54
WRITER'S DIRECT NUMBER:
 (202) 772-8641
INTERNET ADDRESS:
 hcarlson@skgf.com

Commissioner for Patents
 Washington, D.C. 20231

Art Unit 1644

Re: U.S. Utility Patent Application
 Appl. No. 08/452,843; Filed: May 30, 1995
 For: **HLA Binding Peptides and Their Uses**
 Inventors: SETTE *et al.*
 Our Ref: 2060.0010002/EKS/HCC/M-M

RECEIVED

MAR 21 2003

TECH CENTER 1000, 2003

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Second Supplemental Information Disclosure Statement;
2. Form PTO-1449 one (1) page, citing one (1) document;
3. Copy of cited document AS27; and
4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
March 19, 2003
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Helene Carlson

Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Enclosures

::ODMA\MHODMA\SKGF_DC1;113538;1
SKGF Rev. 2/15/02 dcw

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

RECEIVED

MAR 21 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/290

In re application of:

SETTE *et al.*

Appl. No. 08/452,843

Filed: May 30, 1995

For: **HLA Binding Peptides and Their
Uses**

Confirmation No. 5698

Art Unit: 1644

Examiner: DiBrino, M.

Atty. Docket:
2060.0010002/EKS/HCC/M-M

Second Supplemental Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Supplemental Information Disclosure Statement filed on October 2, 2002, in connection with the above-captioned application. A copy of the document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Second Supplemental Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d). No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the document has been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.




Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: 3/19/03

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

::ODMA\MHODMA\SKGF_DC1;113402;1
SKGF Rev. 12/1802 mac; Rev. 03/14/03 svb



SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 2060.0010002/EKS/HCC/M-M		APPLICATION NO. 08/452,843	
		APPLICANT Sette et al.			
		FILING DATE May 30, 1995		GROUP 1644	

U. S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

MAR 21 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS	27	Gnjatic, S., et al., "Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules," <i>Eur. J. Immunol.</i> 25:1638-1642, VCH Verlagsgesellschaft mbH (June 1995).
	AT		

EXAMINER _____ DATE CONSIDERED _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.